Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients,Immunity

当前位置： X-MOL 学术 › Immunity › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Mass cytometry reveals a conserved immune trajectory of recovery in hospitalized COVID-19 patients
Immunity ( IF 25.5 ) Pub Date : 2022-06-07 , DOI: 10.1016/j.immuni.2022.06.004
Cassandra E Burnett ₁ , Trine Line Hauge Okholm ₁ , Iliana Tenvooren ₁ , Diana M Marquez ₁ , Stanley Tamaki ₂ , Priscila Munoz Sandoval ₃ , Andrew Willmore ₄ , , Carolyn M Hendrickson ₅ , Kirsten N Kangelaris ₆ , Charles R Langelier ₇ , Matthew F Krummel ₈ , Prescott G Woodruff ₅ , Carolyn S Calfee ₄ , David J Erle ₉ , K Mark Ansel ₁₀ , Matthew H Spitzer ₁₁

Affiliation

Department of Otolaryngology-Head and Neck Cancer, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Immunology & Immunology and Sandler Asthma Basic Research Center, University of California, San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA.
UCSF CoLabs, University of California, San Francisco, San Francisco, CA 94143, USA.
Department of Immunology & Immunology and Sandler Asthma Basic Research Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA 94110, USA.
Division of Hospital Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA.
Division of Infectious Diseases, University of California, San Francisco, San Francisco, CA 94143, USA.
UCSF CoLabs, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Pathology, University of California, San Francisco, San Francisco, CA 94115, USA; ImmunoX Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
UCSF CoLabs, University of California, San Francisco, San Francisco, CA 94143, USA; Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA; ImmunoX Initiative, University of California, San Francisco, San Francisco, CA 94143, USA; Lung Biology Center, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Institute for Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
Department of Immunology & Immunology and Sandler Asthma Basic Research Center, University of California, San Francisco, San Francisco, CA 94143, USA; ImmunoX Initiative, University of California, San Francisco, San Francisco, CA 94143, USA.
Department of Otolaryngology-Head and Neck Cancer, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Immunology & Immunology and Sandler Asthma Basic Research Center, University of California, San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Department of Pathology, University of California, San Francisco, San Francisco, CA 94115, USA.

While studies have elucidated many pathophysiological elements of COVID-19, little is known about immunological changes during COVID-19 resolution. We analyzed immune cells and phosphorylated signaling states at single-cell resolution from longitudinal blood samples of patients hospitalized with COVID-19, pneumonia and/or sepsis, and healthy individuals by mass cytometry. COVID-19 patients showed distinct immune compositions and an early, coordinated, and elevated immune cell signaling profile associated with early hospital discharge. Intra-patient longitudinal analysis revealed changes in myeloid and T cell frequencies and a reduction in immune cell signaling across cell types that accompanied disease resolution and discharge. These changes, together with increases in regulatory T cells and reduced signaling in basophils, also accompanied recovery from respiratory failure and were associated with better outcomes at time of admission. Therefore, although patients have heterogeneous immunological baselines and highly variable disease courses, a core immunological trajectory exists that defines recovery from severe SARS-CoV-2 infection.

中文翻译：

质谱流式细胞术揭示了住院 COVID-19 患者康复的保守免疫轨迹

虽然研究已经阐明了 COVID-19 的许多病理生理学因素，但人们对 COVID-19 消退期间的免疫学变化知之甚少。我们通过质谱流式分析仪，以单细胞分辨率分析了因 COVID-19、肺炎和/或脓毒症住院患者以及健康个体的纵向血液样本中的免疫细胞和磷酸化信号状态。 COVID-19 患者表现出独特的免疫成分以及与早期出院相关的早期、协调和升高的免疫细胞信号传导谱。患者内部纵向分析揭示了伴随疾病消退和出院的骨髓细胞和 T 细胞频率的变化以及跨细胞类型的免疫细胞信号传导的减少。这些变化，加上调节性 T 细胞的增加和嗜碱性粒细胞信号传导的减少，也伴随着呼吸衰竭的恢复，并与入院时更好的结果相关。因此，尽管患者具有异质的免疫学基线和高度可变的病程，但存在定义严重 SARS-CoV-2 感染恢复的核心免疫学轨迹。

更新日期：2022-06-07

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11